News
2d
Pharmaceutical Technology on MSNEC approves AstraZeneca’s Imfinzi combo for NSCLCThe European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable ...
2d
MyChesCo on MSNFDA Approves AstraZeneca’s IMFINZI® for Muscle-Invasive Bladder CancerAstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer ...
The FDA approved agents in MIBC and neuroendocrine tumors and amivantamab/lazertinib continues to shine in NSCLC.
AstraZeneca saw 18% revenue growth in 2024, boosted by key drugs and global innovation. See here to know why we recommend a ...
The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...
New treatments for Prader-Willi Syndrome and hemophilia; FDA fast tracks a chlamydia vaccine candidate; over-the-counter test cleared for identifying chlamydia, gonorrhea and trichomoniasis.
Several pharma CEOs met with Chinese President Xi Jinping in Beijing. President Donald Trump's reciprocal tariffs have mostly ...
Imfinzi in combination with chemotherapy has been approved in the European Union, EU, for the treatment of adults with ...
The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...
In early corporate news, BP Chair Helge Lund announced his intention to resign, and AstraZeneca received EU approval for two different therapies. Here is what you need to know at the London market ...
Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.
Brian McNamara has a shot at beating his aggressive cancer, but his Aetna subsidiary insurance company doesn't want to pay ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results